APO Research
Talk to an analyst

APO RESEARCH · REPORT

Tuberculosis Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Tuberculosis Drugs Market Outlook and Growth Opportunities 2026

22 December 2025209 pages

Choose your research edition.

Industry ResearchTuberculosis Drugs Industry Research Report 2026137 pages · $2,950 USDIndustry Growth & TrendsGlobal Tuberculosis Drugs Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Tuberculosis Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Tuberculosis Drugs Market Outlook and Growth Opportunities 2026209 pages · $4,250 USDMarket Analysis & ForecastGlobal Tuberculosis Drugs Market Analysis and Forecast 2026-2032204 pages · $4,950 USD

Market perspective

The global Tuberculosis Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Tuberculosis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Tuberculosis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Tuberculosis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Tuberculosis Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Tuberculosis Drugs market include Abbott, Teva Pharmaceutical Industries Ltd, Sanofi, Johnson & Johnson, Novartis AG, Eli Lilly and Company, Pfizer Inc, AstraZeneca Plc and Viatris Inc. (Mylan N.V.), among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Tuberculosis Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Tuberculosis Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Tuberculosis Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Tuberculosis Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Tuberculosis Drugs Segment by Company

Abbott

Teva Pharmaceutical Industries Ltd

Sanofi

Johnson & Johnson

Novartis AG

Eli Lilly and Company

Pfizer Inc

AstraZeneca Plc

Viatris Inc. (Mylan N.V.)

Sun Pharmaceutical Industries Ltd.

Otsuka Pharmaceutical

Macleods Pharmaceuticals Ltd.

Lupin Laboratories Ltd

FRESENIUS SE & Co. KGaA (Fresenius Kabi)

Cipla Ltd

Cadila Pharmaceuticals

ANI Pharmaceuticals, Inc

Alkem Laboratories Ltd

Tuberculosis Drugs Segment by Type

First Line Drugs Therapy

Combination Drugs Therapy

Second Line Drugs Therapy

Tuberculosis Drugs Segment by Application

Hospital

Private Clinic

Others

Tuberculosis Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Tuberculosis Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Tuberculosis Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Tuberculosis Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Tuberculosis Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tuberculosis Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Tuberculosis Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tuberculosis Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Tuberculosis Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Tuberculosis Drugs industry.

Chapter 3: Detailed analysis of Tuberculosis Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Tuberculosis Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Tuberculosis Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Tuberculosis Drugs Industry Trends Table 2. Tuberculosis Drugs Industry Drivers Table 3. Tuberculosis Drugs Industry Opportunities and Challenges Table 4. Tuberculosis Drugs Industry Restraints Table 5. Global Tuberculosis Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Tuberculosis Drugs Revenue Share by Company (2021-2026) Table 7. Global Tuberculosis Drugs Sales Volume by Company (k units) & (2021-2026) Table 8. Global Tuberculosis Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Tuberculosis Drugs Average Price (US$/unit) of Company (2021-2026) Table 10. Global Tuberculosis Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Tuberculosis Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Tuberculosis Drugs Company, Product Type & Application Table 13. Global Tuberculosis Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Tuberculosis Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of First Line Drugs Therapy Table 18. Significant Companies of Combination Drugs Therapy Table 19. Significant Companies of Second Line Drugs Therapy Table 20. Global Tuberculosis Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 21. Global Tuberculosis Drugs Sales Volume by Type (2021-2026) & (k units) Table 22. Global Tuberculosis Drugs Sales Volume by Type (2027-2032) & (k units) Table 23. Global Tuberculosis Drugs Sales Volume Share by Type (2021-2026) Table 24. Global Tuberculosis Drugs Sales Volume Share by Type (2027-2032) Table 25. Global Tuberculosis Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Tuberculosis Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Tuberculosis Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Tuberculosis Drugs Sales Value Share by Type (2021-2026) Table 29. Global Tuberculosis Drugs Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Hospital Table 31. Significant Companies of Private Clinic Table 32. Significant Companies of Others Table 33. Global Tuberculosis Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 34. Global Tuberculosis Drugs Sales Volume by Application (2021-2026) & (k units) Table 35. Global Tuberculosis Drugs Sales Volume by Application (2027-2032) & (k units) Table 36. Global Tuberculosis Drugs Sales Volume Share by Application (2021-2026) Table 37. Global Tuberculosis Drugs Sales Volume Share by Application (2027-2032) Table 38. Global Tuberculosis Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Tuberculosis Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Tuberculosis Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Tuberculosis Drugs Sales Value Share by Application (2021-2026) Table 42. Global Tuberculosis Drugs Sales Value Share by Application (2027-2032) Table 43. Global Tuberculosis Drugs Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 44. Global Tuberculosis Drugs Sales by Region (2021-2026) & (k units) Table 45. Global Tuberculosis Drugs Sales Market Share by Region (2021-2026) Table 46. Global Tuberculosis Drugs Sales by Region (2027-2032) & (k units) Table 47. Global Tuberculosis Drugs Sales Market Share by Region (2027-2032) Table 48. Global Tuberculosis Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Tuberculosis Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Tuberculosis Drugs Sales Value Share by Region (2021-2026) Table 51. Global Tuberculosis Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Tuberculosis Drugs Sales Value Share by Region (2027-2032) Table 53. Global Tuberculosis Drugs Market Average Price (US$/unit) by Region (2021-2026) Table 54. Global Tuberculosis Drugs Market Average Price (US$/unit) by Region (2027-2032) Table 55. Global Tuberculosis Drugs Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 56. Global Tuberculosis Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Tuberculosis Drugs Sales by Country (2021-2026) & (k units) Table 58. Global Tuberculosis Drugs Sales Market Share by Country (2021-2026) Table 59. Global Tuberculosis Drugs Sales by Country (2027-2032) & (k units) Table 60. Global Tuberculosis Drugs Sales Market Share by Country (2027-2032) Table 61. Global Tuberculosis Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Tuberculosis Drugs Sales Value Market Share by Country (2021-2026) Table 63. Global Tuberculosis Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Tuberculosis Drugs Sales Value Market Share by Country (2027-2032) Table 65. Abbott Company Information Table 66. Abbott Business Overview Table 67. Abbott Tuberculosis Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 68. Abbott Tuberculosis Drugs Product Portfolio Table 69. Abbott Recent Development Table 70. Teva Pharmaceutical Industries Ltd Company Information Table 71. Teva Pharmaceutical Industries Ltd Business Overview Table 72. Teva Pharmaceutical Industries Ltd Tuberculosis Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 73. Teva Pharmaceutical Industries Ltd Tuberculosis Drugs Product Portfolio Table 74. Teva Pharmaceutical Industries Ltd Recent Development Table 75. Sanofi Company Information Table 76. Sanofi Business Overview Table 77. Sanofi Tuberculosis Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 78. Sanofi Tuberculosis Drugs Product Portfolio Table 79. Sanofi Recent Development Table 80. Johnson & Johnson Company Information Table 81. Johnson & Johnson Business Overview Table 82. Johnson & Johnson Tuberculosis Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 83. Johnson & Johnson Tuberculosis Drugs Product Portfolio Table 84. Johnson & Johnson Recent Development Table 85. Novartis AG Company Information Table 86. Novartis AG Business Overview Table 87. Novartis AG Tuberculosis Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 88. Novartis AG Tuberculosis Drugs Product Portfolio Table 89. Novartis AG Recent Development Table 90. Eli Lilly and Company Company Information Table 91. Eli Lilly and Company Business Overview Table 92. Eli Lilly and Company Tuberculosis Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 93. Eli Lilly and Company Tuberculosis Drugs Product Portfolio Table 94. Eli Lilly and Company Recent Development Table 95. Pfizer Inc Company Information Table 96. Pfizer Inc Business Overview Table 97. Pfizer Inc Tuberculosis Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 98. Pfizer Inc Tuberculosis Drugs Product Portfolio Table 99. Pfizer Inc Recent Development Table 100. AstraZeneca Plc Company Information Table 101. AstraZeneca Plc Business Overview Table 102. AstraZeneca Plc Tuberculosis Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 103. AstraZeneca Plc Tuberculosis Drugs Product Portfolio Table 104. AstraZeneca Plc Recent Development Table 105. Viatris Inc. (Mylan N.V.) Company Information Table 106. Viatris Inc. (Mylan N.V.) Business Overview Table 107. Viatris Inc. (Mylan N.V.) Tuberculosis Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 108. Viatris Inc. (Mylan N.V.) Tuberculosis Drugs Product Portfolio Table 109. Viatris Inc. (Mylan N.V.) Recent Development Table 110. Sun Pharmaceutical Industries Ltd. Company Information Table 111. Sun Pharmaceutical Industries Ltd. Business Overview Table 112. Sun Pharmaceutical Industries Ltd. Tuberculosis Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 113. Sun Pharmaceutical Industries Ltd. Tuberculosis Drugs Product Portfolio Table 114. Sun Pharmaceutical Industries Ltd. Recent Development Table 115. Otsuka Pharmaceutical Company Information Table 116. Otsuka Pharmaceutical Business Overview Table 117. Otsuka Pharmaceutical Tuberculosis Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 118. Otsuka Pharmaceutical Tuberculosis Drugs Product Portfolio Table 119. Otsuka Pharmaceutical Recent Development Table 120. Macleods Pharmaceuticals Ltd. Company Information Table 121. Macleods Pharmaceuticals Ltd. Business Overview Table 122. Macleods Pharmaceuticals Ltd. Tuberculosis Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 123. Macleods Pharmaceuticals Ltd. Tuberculosis Drugs Product Portfolio Table 124. Macleods Pharmaceuticals Ltd. Recent Development Table 125. Lupin Laboratories Ltd Company Information Table 126. Lupin Laboratories Ltd Business Overview Table 127. Lupin Laboratories Ltd Tuberculosis Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 128. Lupin Laboratories Ltd Tuberculosis Drugs Product Portfolio Table 129. Lupin Laboratories Ltd Recent Development Table 130. FRESENIUS SE & Co. KGaA (Fresenius Kabi) Company Information Table 131. FRESENIUS SE & Co. KGaA (Fresenius Kabi) Business Overview Table 132. FRESENIUS SE & Co. KGaA (Fresenius Kabi) Tuberculosis Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 133. FRESENIUS SE & Co. KGaA (Fresenius Kabi) Tuberculosis Drugs Product Portfolio Table 134. FRESENIUS SE & Co. KGaA (Fresenius Kabi) Recent Development Table 135. Cipla Ltd Company Information Table 136. Cipla Ltd Business Overview Table 137. Cipla Ltd Tuberculosis Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 138. Cipla Ltd Tuberculosis Drugs Product Portfolio Table 139. Cipla Ltd Recent Development Table 140. Cadila Pharmaceuticals Company Information Table 141. Cadila Pharmaceuticals Business Overview Table 142. Cadila Pharmaceuticals Tuberculosis Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 143. Cadila Pharmaceuticals Tuberculosis Drugs Product Portfolio Table 144. Cadila Pharmaceuticals Recent Development Table 145. ANI Pharmaceuticals, Inc Company Information Table 146. ANI Pharmaceuticals, Inc Business Overview Table 147. ANI Pharmaceuticals, Inc Tuberculosis Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 148. ANI Pharmaceuticals, Inc Tuberculosis Drugs Product Portfolio Table 149. ANI Pharmaceuticals, Inc Recent Development Table 150. Alkem Laboratories Ltd Company Information Table 151. Alkem Laboratories Ltd Business Overview Table 152. Alkem Laboratories Ltd Tuberculosis Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 153. Alkem Laboratories Ltd Tuberculosis Drugs Product Portfolio Table 154. Alkem Laboratories Ltd Recent Development Table 155. Key Raw Materials Table 156. Raw Materials Key Suppliers Table 157. Tuberculosis Drugs Distributors List Table 158. Tuberculosis Drugs Customers List Table 159. Research Programs/Design for This Report Table 160. Authors List of This Report Table 161. Secondary Sources Table 162. Primary Sources List of Figures Figure 1. Tuberculosis Drugs Product Image Figure 2. Global Tuberculosis Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Tuberculosis Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Tuberculosis Drugs Sales (2021-2032) & (k units) Figure 5. Global Tuberculosis Drugs Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Tuberculosis Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. First Line Drugs Therapy Image Figure 10. Combination Drugs Therapy Image Figure 11. Second Line Drugs Therapy Image Figure 12. Global Tuberculosis Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 13. Global Tuberculosis Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Tuberculosis Drugs Sales Volume Share by Type (2021-2032) Figure 15. Global Tuberculosis Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Tuberculosis Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Tuberculosis Drugs Sales Value Share by Type (2021-2032) Figure 18. Hospital Image Figure 19. Private Clinic Image Figure 20. Others Image Figure 21. Global Tuberculosis Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 22. Global Tuberculosis Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Tuberculosis Drugs Sales Volume Share by Application (2021-2032) Figure 24. Global Tuberculosis Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Tuberculosis Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Tuberculosis Drugs Sales Value Share by Application (2021-2032) Figure 27. Global Tuberculosis Drugs Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 28. Global Tuberculosis Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Tuberculosis Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Tuberculosis Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Tuberculosis Drugs Sales Value (2021-2032) & (US$ Million) Figure 32. North America Tuberculosis Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Tuberculosis Drugs Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Tuberculosis Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Tuberculosis Drugs Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Tuberculosis Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Tuberculosis Drugs Sales Value (2021-2032) & (US$ Million) Figure 38. South America Tuberculosis Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Tuberculosis Drugs Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Tuberculosis Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Tuberculosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Tuberculosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Tuberculosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Tuberculosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Tuberculosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Tuberculosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Tuberculosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Tuberculosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Tuberculosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Tuberculosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Tuberculosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Tuberculosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Tuberculosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Tuberculosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Tuberculosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Tuberculosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Tuberculosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Tuberculosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Tuberculosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Tuberculosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Tuberculosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Tuberculosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Tuberculosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Tuberculosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Tuberculosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Tuberculosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Tuberculosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Tuberculosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Tuberculosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Tuberculosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Tuberculosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Tuberculosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Tuberculosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Tuberculosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Tuberculosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Tuberculosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Tuberculosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Tuberculosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Tuberculosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Tuberculosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Tuberculosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Tuberculosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Tuberculosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Tuberculosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Tuberculosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Tuberculosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Tuberculosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Tuberculosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Tuberculosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Tuberculosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Tuberculosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Tuberculosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Tuberculosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Tuberculosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Tuberculosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Tuberculosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Tuberculosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Tuberculosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Tuberculosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Tuberculosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Tuberculosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Tuberculosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Tuberculosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Tuberculosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Tuberculosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Tuberculosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Tuberculosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Tuberculosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Tuberculosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Tuberculosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Tuberculosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Tuberculosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Tuberculosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Tuberculosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Tuberculosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Tuberculosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Tuberculosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Tuberculosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Tuberculosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Tuberculosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Tuberculosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Tuberculosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Tuberculosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Tuberculosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Tuberculosis Drugs Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Tuberculosis Drugs Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • First Line Drugs Therapy
  • Combination Drugs Therapy
  • Second Line Drugs Therapy
Applications
  • Hospital
  • Private Clinic
  • Others
Companies covered
  • Abbott
  • Teva Pharmaceutical Industries Ltd
  • Sanofi
  • Johnson & Johnson
  • Novartis AG
  • Eli Lilly and Company
  • Pfizer Inc
  • AstraZeneca Plc
  • Viatris Inc. (Mylan N.V.)
  • Sun Pharmaceutical Industries Ltd.
  • Otsuka Pharmaceutical
  • Macleods Pharmaceuticals Ltd.
  • Lupin Laboratories Ltd
  • FRESENIUS SE & Co. KGaA (Fresenius Kabi)
  • Cipla Ltd
  • Cadila Pharmaceuticals
  • ANI Pharmaceuticals, Inc
  • Alkem Laboratories Ltd

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Tuberculosis Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Tuberculosis Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Tuberculosis Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Tuberculosis Drugs Market Dynamics
  1. 2.1 Tuberculosis Drugs Industry Trends
  2. 2.2 Tuberculosis Drugs Industry Drivers
  3. 2.3 Tuberculosis Drugs Industry Opportunities and Challenges
  4. 2.4 Tuberculosis Drugs Industry Restraints
3 Tuberculosis Drugs Market by Company
  1. 3.1 Global Tuberculosis Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Tuberculosis Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Tuberculosis Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Tuberculosis Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Tuberculosis Drugs Company Ranking (2024-2026)
  6. 3.6 Global Tuberculosis Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Tuberculosis Drugs Company Product Type and Application
  8. 3.8 Global Tuberculosis Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Tuberculosis Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Tuberculosis Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Tuberculosis Drugs Market by Type
  1. 4.1 Tuberculosis Drugs Type Introduction
  2. 4.1.1 First Line Drugs Therapy
  3. 4.1.2 Combination Drugs Therapy
  4. 4.1.3 Second Line Drugs Therapy
  5. 4.2 Global Tuberculosis Drugs Sales Volume by Type
  6. 4.2.1 Global Tuberculosis Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Tuberculosis Drugs Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Tuberculosis Drugs Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Tuberculosis Drugs Sales Value by Type
  10. 4.3.1 Global Tuberculosis Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Tuberculosis Drugs Sales Value by Type (2021-2032)
  12. 4.3.3 Global Tuberculosis Drugs Sales Value Share by Type (2021-2032)
5 Tuberculosis Drugs Market by Application
  1. 5.1 Tuberculosis Drugs Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Private Clinic
  4. 5.1.3 Others
  5. 5.2 Global Tuberculosis Drugs Sales Volume by Application
  6. 5.2.1 Global Tuberculosis Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Tuberculosis Drugs Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Tuberculosis Drugs Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Tuberculosis Drugs Sales Value by Application
  10. 5.3.1 Global Tuberculosis Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Tuberculosis Drugs Sales Value by Application (2021-2032)
  12. 5.3.3 Global Tuberculosis Drugs Sales Value Share by Application (2021-2032)
6 Tuberculosis Drugs Regional Sales and Value Analysis
  1. 6.1 Global Tuberculosis Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Tuberculosis Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Tuberculosis Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Tuberculosis Drugs Sales by Region (2027-2032)
  5. 6.3 Global Tuberculosis Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Tuberculosis Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Tuberculosis Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Tuberculosis Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Tuberculosis Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Tuberculosis Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Tuberculosis Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Tuberculosis Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Tuberculosis Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Tuberculosis Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Tuberculosis Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Tuberculosis Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Tuberculosis Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Tuberculosis Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Tuberculosis Drugs Sales Value Share by Country, 2025 VS 2032
7 Tuberculosis Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Tuberculosis Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Tuberculosis Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Tuberculosis Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Tuberculosis Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Tuberculosis Drugs Sales by Country (2027-2032)
  6. 7.4 Global Tuberculosis Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Tuberculosis Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Tuberculosis Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Tuberculosis Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Tuberculosis Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Tuberculosis Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Tuberculosis Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Tuberculosis Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Tuberculosis Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Tuberculosis Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Tuberculosis Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Tuberculosis Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Tuberculosis Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Tuberculosis Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Tuberculosis Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Tuberculosis Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Tuberculosis Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Tuberculosis Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Tuberculosis Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Tuberculosis Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Tuberculosis Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Tuberculosis Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Tuberculosis Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Tuberculosis Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Tuberculosis Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Tuberculosis Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Tuberculosis Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Tuberculosis Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Tuberculosis Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Tuberculosis Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Tuberculosis Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Tuberculosis Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Tuberculosis Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Tuberculosis Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Tuberculosis Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Tuberculosis Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Tuberculosis Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Tuberculosis Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Tuberculosis Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Tuberculosis Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Tuberculosis Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Tuberculosis Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Tuberculosis Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Tuberculosis Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Tuberculosis Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Tuberculosis Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Tuberculosis Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Tuberculosis Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Tuberculosis Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Tuberculosis Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Tuberculosis Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Tuberculosis Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Tuberculosis Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Tuberculosis Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Tuberculosis Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Tuberculosis Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Tuberculosis Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Tuberculosis Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Tuberculosis Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Tuberculosis Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Tuberculosis Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Tuberculosis Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Tuberculosis Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Tuberculosis Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Tuberculosis Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Tuberculosis Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Tuberculosis Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Tuberculosis Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Tuberculosis Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Tuberculosis Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Tuberculosis Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Tuberculosis Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Tuberculosis Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Tuberculosis Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Tuberculosis Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Tuberculosis Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Tuberculosis Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Tuberculosis Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Tuberculosis Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Tuberculosis Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Tuberculosis Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Tuberculosis Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Tuberculosis Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Tuberculosis Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Tuberculosis Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Tuberculosis Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Tuberculosis Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Abbott
  2. 8.1.1 Abbott Company Information
  3. 8.1.2 Abbott Business Overview
  4. 8.1.3 Abbott Tuberculosis Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Abbott Tuberculosis Drugs Product Portfolio
  6. 8.1.5 Abbott Recent Developments
  7. 8.2 Teva Pharmaceutical Industries Ltd
  8. 8.2.1 Teva Pharmaceutical Industries Ltd Company Information
  9. 8.2.2 Teva Pharmaceutical Industries Ltd Business Overview
  10. 8.2.3 Teva Pharmaceutical Industries Ltd Tuberculosis Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Teva Pharmaceutical Industries Ltd Tuberculosis Drugs Product Portfolio
  12. 8.2.5 Teva Pharmaceutical Industries Ltd Recent Developments
  13. 8.3 Sanofi
  14. 8.3.1 Sanofi Company Information
  15. 8.3.2 Sanofi Business Overview
  16. 8.3.3 Sanofi Tuberculosis Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi Tuberculosis Drugs Product Portfolio
  18. 8.3.5 Sanofi Recent Developments
  19. 8.4 Johnson & Johnson
  20. 8.4.1 Johnson & Johnson Company Information
  21. 8.4.2 Johnson & Johnson Business Overview
  22. 8.4.3 Johnson & Johnson Tuberculosis Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Johnson & Johnson Tuberculosis Drugs Product Portfolio
  24. 8.4.5 Johnson & Johnson Recent Developments
  25. 8.5 Novartis AG
  26. 8.5.1 Novartis AG Company Information
  27. 8.5.2 Novartis AG Business Overview
  28. 8.5.3 Novartis AG Tuberculosis Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Novartis AG Tuberculosis Drugs Product Portfolio
  30. 8.5.5 Novartis AG Recent Developments
  31. 8.6 Eli Lilly and Company
  32. 8.6.1 Eli Lilly and Company Company Information
  33. 8.6.2 Eli Lilly and Company Business Overview
  34. 8.6.3 Eli Lilly and Company Tuberculosis Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Eli Lilly and Company Tuberculosis Drugs Product Portfolio
  36. 8.6.5 Eli Lilly and Company Recent Developments
  37. 8.7 Pfizer Inc
  38. 8.7.1 Pfizer Inc Company Information
  39. 8.7.2 Pfizer Inc Business Overview
  40. 8.7.3 Pfizer Inc Tuberculosis Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Pfizer Inc Tuberculosis Drugs Product Portfolio
  42. 8.7.5 Pfizer Inc Recent Developments
  43. 8.8 AstraZeneca Plc
  44. 8.8.1 AstraZeneca Plc Company Information
  45. 8.8.2 AstraZeneca Plc Business Overview
  46. 8.8.3 AstraZeneca Plc Tuberculosis Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 AstraZeneca Plc Tuberculosis Drugs Product Portfolio
  48. 8.8.5 AstraZeneca Plc Recent Developments
  49. 8.9 Viatris Inc. (Mylan N.V.)
  50. 8.9.1 Viatris Inc. (Mylan N.V.) Company Information
  51. 8.9.2 Viatris Inc. (Mylan N.V.) Business Overview
  52. 8.9.3 Viatris Inc. (Mylan N.V.) Tuberculosis Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Viatris Inc. (Mylan N.V.) Tuberculosis Drugs Product Portfolio
  54. 8.9.5 Viatris Inc. (Mylan N.V.) Recent Developments
  55. 8.10 Sun Pharmaceutical Industries Ltd.
  56. 8.10.1 Sun Pharmaceutical Industries Ltd. Company Information
  57. 8.10.2 Sun Pharmaceutical Industries Ltd. Business Overview
  58. 8.10.3 Sun Pharmaceutical Industries Ltd. Tuberculosis Drugs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Sun Pharmaceutical Industries Ltd. Tuberculosis Drugs Product Portfolio
  60. 8.10.5 Sun Pharmaceutical Industries Ltd. Recent Developments
  61. 8.11 Otsuka Pharmaceutical
  62. 8.11.1 Otsuka Pharmaceutical Company Information
  63. 8.11.2 Otsuka Pharmaceutical Business Overview
  64. 8.11.3 Otsuka Pharmaceutical Tuberculosis Drugs Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Otsuka Pharmaceutical Tuberculosis Drugs Product Portfolio
  66. 8.11.5 Otsuka Pharmaceutical Recent Developments
  67. 8.12 Macleods Pharmaceuticals Ltd.
  68. 8.12.1 Macleods Pharmaceuticals Ltd. Company Information
  69. 8.12.2 Macleods Pharmaceuticals Ltd. Business Overview
  70. 8.12.3 Macleods Pharmaceuticals Ltd. Tuberculosis Drugs Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Macleods Pharmaceuticals Ltd. Tuberculosis Drugs Product Portfolio
  72. 8.12.5 Macleods Pharmaceuticals Ltd. Recent Developments
  73. 8.13 Lupin Laboratories Ltd
  74. 8.13.1 Lupin Laboratories Ltd Company Information
  75. 8.13.2 Lupin Laboratories Ltd Business Overview
  76. 8.13.3 Lupin Laboratories Ltd Tuberculosis Drugs Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Lupin Laboratories Ltd Tuberculosis Drugs Product Portfolio
  78. 8.13.5 Lupin Laboratories Ltd Recent Developments
  79. 8.14 FRESENIUS SE & Co. KGaA (Fresenius Kabi)
  80. 8.14.1 FRESENIUS SE & Co. KGaA (Fresenius Kabi) Company Information
  81. 8.14.2 FRESENIUS SE & Co. KGaA (Fresenius Kabi) Business Overview
  82. 8.14.3 FRESENIUS SE & Co. KGaA (Fresenius Kabi) Tuberculosis Drugs Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 FRESENIUS SE & Co. KGaA (Fresenius Kabi) Tuberculosis Drugs Product Portfolio
  84. 8.14.5 FRESENIUS SE & Co. KGaA (Fresenius Kabi) Recent Developments
  85. 8.15 Cipla Ltd
  86. 8.15.1 Cipla Ltd Company Information
  87. 8.15.2 Cipla Ltd Business Overview
  88. 8.15.3 Cipla Ltd Tuberculosis Drugs Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Cipla Ltd Tuberculosis Drugs Product Portfolio
  90. 8.15.5 Cipla Ltd Recent Developments
  91. 8.16 Cadila Pharmaceuticals
  92. 8.16.1 Cadila Pharmaceuticals Company Information
  93. 8.16.2 Cadila Pharmaceuticals Business Overview
  94. 8.16.3 Cadila Pharmaceuticals Tuberculosis Drugs Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Cadila Pharmaceuticals Tuberculosis Drugs Product Portfolio
  96. 8.16.5 Cadila Pharmaceuticals Recent Developments
  97. 8.17 ANI Pharmaceuticals, Inc
  98. 8.17.1 ANI Pharmaceuticals, Inc Company Information
  99. 8.17.2 ANI Pharmaceuticals, Inc Business Overview
  100. 8.17.3 ANI Pharmaceuticals, Inc Tuberculosis Drugs Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 ANI Pharmaceuticals, Inc Tuberculosis Drugs Product Portfolio
  102. 8.17.5 ANI Pharmaceuticals, Inc Recent Developments
  103. 8.18 Alkem Laboratories Ltd
  104. 8.18.1 Alkem Laboratories Ltd Company Information
  105. 8.18.2 Alkem Laboratories Ltd Business Overview
  106. 8.18.3 Alkem Laboratories Ltd Tuberculosis Drugs Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Alkem Laboratories Ltd Tuberculosis Drugs Product Portfolio
  108. 8.18.5 Alkem Laboratories Ltd Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Tuberculosis Drugs Value Chain Analysis
  2. 9.1.1 Tuberculosis Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Tuberculosis Drugs Sales Mode & Process
  6. 9.2 Tuberculosis Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Tuberculosis Drugs Distributors
  9. 9.2.3 Tuberculosis Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst